Advertisement

Clinical & Experimental Metastasis

, Volume 23, Issue 1, pp 9–18 | Cite as

RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4

  • Eliane Shizuka Nakamura
  • Keiichi Koizumi
  • Mitsuo Kobayashi
  • Yurika Saitoh
  • Yoshihisa Arita
  • Takashi Nakayama
  • Hiroaki Sakurai
  • Osamu Yoshie
  • Ikuo Saiki
Original Paper

Abstract

Chemokines are now known to play an important role in cancer growth and metastasis. Here we report that differentiating osteoclasts constitutively produce CCL22 (also called macrophage-derived chemokine) and potentially promote bone metastasis of lung cancer expressing its receptor CCR4. We first examined expression of chemokines by differentiating osteoclasts. CCL22 was selectively upregulated in osteoclast-like cells derived from RAW264.7 cells and mouse bone marrow cells upon stimulation with RANKL (receptor activator of nuclear factor-κB ligand). In addition, a human lung cancer cell line SBC-5 that efficiently metastasized to bone when intravenously injected into NK cell-depleted SCID mice was found to express CCR4. Stimulation of SBC-5 cells with CCL22 induced cell migration and also enhanced phosphorylation of protein kinase B/Akt and extracellular signal-regulated kinase (ERK). Furthermore, immunohistochemical analysis of bone metastasis lesions demonstrated close co-localization of tartrate-resistant alkaline phosphatase (TRAP)-positive osteoclasts expressing CCL22 and SBC-5 cells expressing CCR4. Collectively, these results suggest that osteoclasts may promote bone metastasis of cancer cells expressing CCR4 in the bone marrow by producing its ligand CCL22.

Keywords

Osteoclast differentiation CCL22/MDC CCR4 Bone metastasis Human lung cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgments

We thank Dr. Ryohei Ogawa (Department of Radiological Sciences, Faculty of Medicine) and Dr. Tatsuro Miyahara (Department of Toxicology, Faculty of Pharmaceutical Sciences) for helpful advice and Mr. Mamoru Nakamura and Dr. Hikaru Seto (Department of Radiology, Faculty of Medicine, Toyama Medical and Pharmaceutical University), Mr. Iwamoto Shinichi (Applied Medical Research Laboratory) for technical support. The authors also express their appreciation to Dr. Yoichi Kameda (Department of Pathology, Kanagawa Cancer Center), Dr. Kenya Shitara (Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd), Dr. Kouji Matsushima (Department of Molecular Preventive Medicine, School of Medicine, The University of Tokyo) and Dr. Ryuzo Ueda (Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science) for helpful suggestions.

References

  1. 1.
    Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148–149PubMedGoogle Scholar
  2. 2.
    Nicolson GL (1988) Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7:143–188PubMedCrossRefGoogle Scholar
  3. 3.
    Nicolson GL (1988) Differential organ tissue adhesion, invasion, and growth properties of metastatic rat mammary adenocarcinoma cells. Breast Cancer Res Treat 12:167–176PubMedCrossRefGoogle Scholar
  4. 4.
    Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664PubMedCrossRefGoogle Scholar
  5. 5.
    Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593PubMedCrossRefGoogle Scholar
  6. 6.
    Yoneda T (2000) Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5:75–81PubMedCrossRefGoogle Scholar
  7. 7.
    Muller A, Homey B, Soto H et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56PubMedCrossRefGoogle Scholar
  8. 8.
    Yoshie O, Imai T, Nomiyama H (1997) Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol 626:634–644Google Scholar
  9. 9.
    Taichman RS, Cooper C, Keller ET et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832–1837PubMedGoogle Scholar
  10. 10.
    Mochizuki H, Matsubara A, Teishima J et al. (2004) Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 320:656–663PubMedCrossRefGoogle Scholar
  11. 11.
    Li H, Miyahara T, Tezuka Y et al. (1999) The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull 22:391–396PubMedGoogle Scholar
  12. 12.
    Burstone MS (1958) Histochemical demonstration of acid phosphatases with naphthol AS-phosphates. J Natl Cancer Inst 21:523–539PubMedGoogle Scholar
  13. 13.
    Miki T, Yano S, Hanibuchi M et al. (2000) Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 12:209–217PubMedGoogle Scholar
  14. 14.
    Nakamura ES, Koizumi K, Kobayashi M et al. (2004) Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci 95:25–31PubMedCrossRefGoogle Scholar
  15. 15.
    Barlic J, McDermott DH, Merrell MN et al. (2004) Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms. J Biol Chem 279:48,520–48,534Google Scholar
  16. 16.
    Lean JM, Murphy C, Fuller K et al. (2002) CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem 87:386–393PubMedCrossRefGoogle Scholar
  17. 17.
    Okamatsu Y, Kim D, Battaglino R et al. (2004) MIP-1 gamma␣promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol 173:2084–2090PubMedGoogle Scholar
  18. 18.
    Mantovani A, Gray PA, Van Damme J et al. (2000) Macrophage-derived chemokine (MDC). J Leukoc Biol 68:400–404PubMedGoogle Scholar
  19. 19.
    Chan TO, Rittenhouse SE, Tsichlis PN (1999) AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68:965–1014PubMedCrossRefGoogle Scholar
  20. 20.
    Zhou Y, Larsen PH, Hao C et al. (2002) CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J␣Biol Chem 277:49,481–49,487Google Scholar
  21. 21.
    Zhou H, Li XM, Meinkoth J et al. (2000) Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151:483–94PubMedCrossRefGoogle Scholar
  22. 22.
    Porcile C, Bajetto A, Barbero S et al. (2004) CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann N Y Acad Sci 1030:162–169PubMedCrossRefGoogle Scholar
  23. 23.
    Scotton CJ, Wilson JL, Scott K et al. (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62:5930–5938PubMedGoogle Scholar
  24. 24.
    Eisenhardt A, Frey U, Tack M et al. (2005) Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol 47:111–117PubMedCrossRefGoogle Scholar
  25. 25.
    Li YM, Pan Y, Wei Y, Cheng X et al. (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6:459–469PubMedCrossRefGoogle Scholar
  26. 26.
    Benovic JL, Marchese A (2004) A new key in breast cancer metastasis. Cancer Cell 6:429–430PubMedCrossRefGoogle Scholar
  27. 27.
    Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36:71–78PubMedCrossRefGoogle Scholar
  28. 28.
    Uchida D, Begum NM, Tomizuka Y et al. (2004) Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest 84:1538–1546PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006 2006

Authors and Affiliations

  • Eliane Shizuka Nakamura
    • 1
    • 2
  • Keiichi Koizumi
    • 1
  • Mitsuo Kobayashi
    • 1
  • Yurika Saitoh
    • 1
  • Yoshihisa Arita
    • 1
  • Takashi Nakayama
    • 3
  • Hiroaki Sakurai
    • 1
    • 2
  • Osamu Yoshie
    • 3
  • Ikuo Saiki
    • 1
    • 2
  1. 1.Division of Pathogenic Biochemistry, Institute of Natural MedicineUniversity of Toyama ToyamaJapan
  2. 2.The 21st Century COE ProgramUniversity of ToyamaToyamaJapan
  3. 3.Department of Microbiology & SORST Kinki University School of MedicineOsaka Japan

Personalised recommendations